BRPI0923567A2 - agentes antibactericidas novos para o tratamento de infecções gram positivas - Google Patents

agentes antibactericidas novos para o tratamento de infecções gram positivas

Info

Publication number
BRPI0923567A2
BRPI0923567A2 BRPI0923567A BRPI0923567A BRPI0923567A2 BR PI0923567 A2 BRPI0923567 A2 BR PI0923567A2 BR PI0923567 A BRPI0923567 A BR PI0923567A BR PI0923567 A BRPI0923567 A BR PI0923567A BR PI0923567 A2 BRPI0923567 A2 BR PI0923567A2
Authority
BR
Brazil
Prior art keywords
treatment
antibacterial agents
gram positive
new antibacterial
positive infections
Prior art date
Application number
BRPI0923567A
Other languages
English (en)
Inventor
Andre Lee Pearson
Chester A Metcalf Iii
Jing Li
Original Assignee
Cubist Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cubist Pharm Inc filed Critical Cubist Pharm Inc
Publication of BRPI0923567A2 publication Critical patent/BRPI0923567A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/02Peptides of undefined number of amino acids; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/60Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation occurring through the 4-amino group of 2,4-diamino-butanoic acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64Cyclic peptides containing only normal peptide links
    • C07K7/645Cyclosporins; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BRPI0923567A 2008-12-22 2009-12-18 agentes antibactericidas novos para o tratamento de infecções gram positivas BRPI0923567A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13987508P 2008-12-22 2008-12-22
PCT/US2009/068747 WO2010075215A1 (en) 2008-12-22 2009-12-18 Novel antibacterial agents for the treatment of gram positive infections

Publications (1)

Publication Number Publication Date
BRPI0923567A2 true BRPI0923567A2 (pt) 2016-09-27

Family

ID=41718893

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0923567A BRPI0923567A2 (pt) 2008-12-22 2009-12-18 agentes antibactericidas novos para o tratamento de infecções gram positivas

Country Status (27)

Country Link
US (3) US8507647B2 (pt)
EP (2) EP2379580B1 (pt)
JP (1) JP5670914B2 (pt)
KR (1) KR101717795B1 (pt)
CN (1) CN102325787B (pt)
AR (1) AR074833A1 (pt)
AU (1) AU2009330245C1 (pt)
BR (1) BRPI0923567A2 (pt)
CA (1) CA2747965C (pt)
CY (1) CY1114883T1 (pt)
DK (1) DK2379580T3 (pt)
ES (1) ES2442167T3 (pt)
HK (1) HK1161886A1 (pt)
HR (1) HRP20131170T1 (pt)
IL (1) IL213638A0 (pt)
MX (1) MX2011006803A (pt)
NZ (1) NZ594019A (pt)
PL (1) PL2379580T3 (pt)
PT (1) PT2379580E (pt)
RS (1) RS53152B (pt)
RU (1) RU2512396C2 (pt)
SG (1) SG172299A1 (pt)
SI (1) SI2379580T1 (pt)
SM (1) SMT201400037B (pt)
TW (1) TWI444198B (pt)
WO (1) WO2010075215A1 (pt)
ZA (1) ZA201104693B (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013030369A2 (pt) * 2011-05-26 2016-12-13 Cubist Pharm Inc composições de cb-183,315 e métodos relacionados
US10377699B2 (en) * 2013-11-06 2019-08-13 The University Of Hong Kong Daptomycin analogues and a method for the preparation of daptomycin or a daptomycin analogue
WO2015172047A1 (en) * 2014-05-08 2015-11-12 Merck Sharp & Dohme Corp. Cyclic peptide compounds and related methods, salts and compositions
US11667674B2 (en) 2016-04-08 2023-06-06 Versitech Limited Antibacterial cyclic lipopeptides
US10647746B2 (en) 2016-04-08 2020-05-12 Versitech Limited Antibacterial cyclic lipopeptides
PT3445767T (pt) * 2016-04-22 2020-05-13 Astrazeneca Ab Inibidores de mcl-1 macrocíclicos para o tratamento de cancro
US10098890B2 (en) 2016-10-29 2018-10-16 Cipla Limited Stable carfilzomib formulations
IT201600127655A1 (it) 2016-12-16 2018-06-16 Gnosis Spa Processo per la purificazione di antibiotici lipopolipeptidici
US10072045B1 (en) 2017-06-26 2018-09-11 Ramapo Pharmaceuticals, Inc. Antibacterial lipopeptides and methods for their preparation and use
US10526343B2 (en) 2018-03-26 2020-01-07 University Of Sharjah Heterocyclic systems and pharmaceutical applications thereof
RU2762182C1 (ru) * 2020-12-08 2021-12-16 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт по изысканию новых антибиотиков имени Г.Ф. Гаузе" Гауземицины А и В - гликолипопептидные антибактериальные антибиотики и способ их получения

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
USRE32333E (en) 1978-10-16 1987-01-20 Eli Lilly And Company A-21978 Antibiotics and process for their production
USRE32455E (en) 1978-10-16 1987-07-07 Eli Lilly And Company A-21978 antibiotics and process for their production
AU563067B2 (en) 1982-02-27 1987-06-25 Beecham Group Plc Heterocyclic normonyl derivatives
USRE32310E (en) 1982-05-21 1986-12-16 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
IL68700A0 (en) 1982-05-21 1983-09-30 Lilly Co Eli Improvements relating to a-21978c cyclic peptide derivatives and their production
US4482487A (en) 1982-05-21 1984-11-13 Eli Lilly And Company A-21978C cyclic peptides
US4524135A (en) 1982-05-21 1985-06-18 Eli Lilly And Company A-21978C cyclic peptides
US4537717A (en) 1982-05-21 1985-08-27 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
US4399067A (en) 1982-05-21 1983-08-16 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
USRE32311E (en) 1982-05-21 1986-12-16 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
US4396543A (en) * 1982-05-21 1983-08-02 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
SU1452484A3 (ru) 1984-10-09 1989-01-15 Эли Лилли Энд Компани (Фирма) Способ получени производных антибиотиков А-21978С, штамм стрептомицета SтRертомYсеS RoSeoSpoRUS, используемый дл получени антибиотических веществ А-21978С
ZA883887B (en) 1987-06-10 1990-02-28 Lilly Co Eli Chromatographic purification process
US5039660A (en) 1988-03-02 1991-08-13 Endocon, Inc. Partially fused peptide pellet
CA2043762C (en) 1990-06-07 2001-05-29 Adam J. Kreuzman Lipopeptide deacylase
AU7497594A (en) 1993-08-13 1995-03-14 Smithkline Beecham Plc Derivatives of monic acids a and c having antibacterial, antimycoplasmatical, antifungal and herbicidal activity
DE4411025A1 (de) 1994-03-30 1995-10-05 Hoechst Ag Lipopeptid-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung
KR100545506B1 (ko) 1996-03-08 2006-10-04 아스테라스 세이야쿠 가부시키가이샤 환상 리포펩티드 물질의 탈아실화 방법
DE19807972A1 (de) 1998-02-25 1999-08-26 Hoechst Marion Roussel De Gmbh Lipopeptidantibiotika-Calciumsalze, Verfahren zu ihrer Herstellung und Verwendung
KR20100051735A (ko) 1998-09-25 2010-05-17 큐비스트 파마슈티컬즈 인코포레이티드 항생제의 투여 방법
AU3434501A (en) 1999-11-03 2001-05-14 Whitaker Corporation, The Optoelectric module for multi-fiber arrays
EP1884520A3 (en) 1999-12-15 2008-03-05 Cubist Pharmaceuticals, Inc. Daptomycin analogs as antibacterial agents
JP2003517003A (ja) * 1999-12-15 2003-05-20 キュービスト ファーマシューティカルズ, インコーポレイテッド ダプトマイシンアナログおよび抗菌剤としてのそれらの使用
IL150225A0 (en) 1999-12-15 2002-12-01 Cubist Pharm Inc Lipopeptides, pharmaceutical compositions containing the same and methods for the production thereof
US20060014674A1 (en) * 2000-12-18 2006-01-19 Dennis Keith Methods for preparing purified lipopeptides
AU2002353775A1 (en) 2001-08-06 2003-03-10 Cubist Pharmaceuticals, Inc. Lipopeptide stereoisomers, methods for preparing same, and useful intermediates
CA2587848A1 (en) * 2004-11-12 2006-10-19 Cubist Pharmaceuticals, Inc. Antiinfective lipopeptides

Also Published As

Publication number Publication date
ES2442167T3 (es) 2014-02-10
KR101717795B1 (ko) 2017-03-17
KR20110114592A (ko) 2011-10-19
JP2012513467A (ja) 2012-06-14
MX2011006803A (es) 2011-09-06
NZ594019A (en) 2013-08-30
AR074833A1 (es) 2011-02-16
AU2009330245B2 (en) 2013-05-02
WO2010075215A1 (en) 2010-07-01
RU2512396C2 (ru) 2014-04-10
CA2747965A1 (en) 2010-07-01
SMT201400037B (it) 2014-05-07
JP5670914B2 (ja) 2015-02-18
TWI444198B (zh) 2014-07-11
ZA201104693B (en) 2013-01-30
RS53152B (en) 2014-06-30
RU2011130278A (ru) 2013-01-27
AU2009330245A1 (en) 2011-08-04
EP2674437A1 (en) 2013-12-18
HRP20131170T1 (hr) 2014-01-03
TW201028161A (en) 2010-08-01
US20100184649A1 (en) 2010-07-22
SI2379580T1 (sl) 2014-02-28
IL213638A0 (en) 2011-07-31
CN102325787A (zh) 2012-01-18
HK1161886A1 (en) 2012-08-10
US8507647B2 (en) 2013-08-13
US20140073558A1 (en) 2014-03-13
PT2379580E (pt) 2014-01-20
SG172299A1 (en) 2011-07-28
EP2379580A1 (en) 2011-10-26
PL2379580T3 (pl) 2014-05-30
CY1114883T1 (el) 2016-12-14
DK2379580T3 (da) 2014-01-20
CN102325787B (zh) 2014-05-28
US20150337013A1 (en) 2015-11-26
CA2747965C (en) 2017-06-27
EP2379580B1 (en) 2013-10-23
AU2009330245C1 (en) 2013-09-26

Similar Documents

Publication Publication Date Title
BRPI0923567A2 (pt) agentes antibactericidas novos para o tratamento de infecções gram positivas
ES2898695T8 (es) Derivados de benzoxaborol para el tratamiento de infecciones bacterianas
SMT201500117B (it) Composti antibatterici
BR112012002628A2 (pt) "composição para tratamento de infecções por hbv"
BR112013014943A2 (pt) compostos úteis para o tratamento de aids
DK2982696T3 (da) Behandling af akut lymfoblastær leukæmi
BRPI0822625A2 (pt) "dispositivo espaçador modular para o tratamento de infecções por próteses"
BRPI0911923A2 (pt) dispositivos filamentosos para o tratamento de defeitos vasculares
BRPI1015203A2 (pt) agentes antimicrobianos
ZA201100705B (en) Antibacterial combination therapy for the treatment of gram positive bacterial infections
BRPI1009783A2 (pt) compostos para o tratamento de distúrbios metabólicos.
BRPI0813670A2 (pt) Compostos para tratamento
DOP2010000373A (es) Derivados de urea heterociclicos para el tratamiento de infecciones bacterianas
BRPI1013245A2 (pt) "composto para o tratamento de distúrbios metabólicos"
BR112012008959A2 (pt) tratamento de terapia de combinação para infecções virais
BRPI0912687A2 (pt) uso de bactéria probiótica para o tratamento de hiperhomocisteinaemia
BRPI1009448A2 (pt) combinações farmacêuticas compreendendo edea119/bay 869766 para o tratamento de cânceres específicos
BRPI0914139A2 (pt) composições pediátricas para o tratamento de esclerose múltipla
BRPI0912679A2 (pt) composição farmacêutica para o tratamento de fibromialgia
BR112012002267A2 (pt) compostos para o tratamento de inflamação.
EP2271328A4 (en) ANTISEPTIC COMPOSITIONS FOR THE TREATMENT OF INFECTIONS
BRPI0812105A2 (pt) Neramexano para o tratamento de nistagmo
ZA201100468B (en) The treatment of helminthic infections
DK2321306T3 (da) 3-Cyanopyrrolidinyl-phenyl-oxazolidinoner som antibakterielle midler
DK2722053T3 (da) Antibakterielt middel til behandling af infektionssygdomme af bakteriel oprindelse

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: MERCK SHARP AND DOHME CORP. (US)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements